Pacing therapy reduces heart rate and increases heart rate variability in CHF patients

Auricchio, Angelo; Carlson, Gerrard; Kadhiresan, V.; Hoersch, Walter; Spinelli, Julio; investigators, Path-Chf

doi:10.1016/s1071-9164(99)91506-3

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another interesting aspect of the PATH‐CHF data is the changes in heart rate during the resynchronization therapy 37 . Preliminary data show an increase in heart rate variability and a decrease in the resting heart rate when the coordination therapy was active; by contrast, during the off‐phase, an almost complete reversion was observed.…”

Section: Chronic Resultsmentioning

confidence: 99%

Cardiac Resynchronization for Heart Failure: Present Status

Auricchio

Spinelli

2000

Congestive Heart Failure

Self Cite

View full text Add to dashboard Cite

Ventricular dysfunction is a hallmark of heart failure, and is often linked to ventricular dilatation and ventricular conduction delays. Recent studies have demonstrated that systolic function can be improved in patients with left bundle branch block by pre-exciting the site of late activation, usually the left ventricular free wall. Furthermore, it has been recently reported that this improvement is associated with a decrease in myocardial oxygen consumption. We hypothesize that the pre-excitation of the region covered by the blocked bundle acts as an "electrical bypass," resynchronizing the contraction of the septum and the left ventricular free wall. In addition, optimization of the electronic atrioventricular delay allows the simultaneous resynchronization of the atrioventricular contractions, and minimization of diastolic mitral regurgitation. Systolic mitral regurgitation may also be reduced by removing the geometric distortion introduced by the left bundle branch block. The recently reported positive outcome of the PATH-CHF I controlled trial reinforces that the positive acute and chronic results that have been reported up to now may translate into long-term clinical benefit for patients with heart failure and conduction defects. Larger studies are needed to confirm these initial results and to establish the impact of this new therapeutic modality on morbidity and mortality. (c)2000 by CHF, Inc.

show abstract

Section: Chronic Resultsmentioning

confidence: 99%

Cardiac Resynchronization for Heart Failure: Present Status

Auricchio

Spinelli

2000

Congestive Heart Failure

Self Cite

View full text Add to dashboard Cite

show abstract

“…In der VIGOR-CHF-Studie konnten Saxon et al [28] zeigen, dass die Resynchronisationstherapie einen positiven Effekt auf die neurohumorale Aktivierung hat: Unter der Stimulationstherapie nahmen die Katecholamine im Plasma deutlich ab. In der PATH-CHF-Studie konnten eine Abnahme der Ruheherzfrequenz und eine Zunahme in der Herzfrequenzvariabilität beobachtet werden [4]. Higgins et al [16] berichteten über eine signifikante Abnahme von therapiebedürftigen Arrhythmieereignissen mit weniger Schockabgaben der implantierbaren Kardioverter/Defibrillatoren unter der Snychronisationstherapie als Hinweis auf einen positiven Effekt gegen den plötzlichen Herztod.…”

Section: Klinische Ergebnisse Der Stimulationstherapieunclassified

Die kardiale Resynchronisationstherapie bei terminaler Herzinsuffizienz Aktueller Stand und Perspektiven

Sack¹,

Heinzel²,

Dagres³

et al. 2001

Herz

View full text Add to dashboard Cite

The prognosis of patients with end-stage heart failure is limited by two determinants: myocardial pump failure and sudden (arrhythmogenic) cardiac death. Due to the fact that the incidence for sudden cardiac death is considerably high in patients with end-stage heart failure it is reasonable to include the implantation of cardioverters/defibrillaters (ICD) in the concept of biventricular stimulation.

show abstract